Mini-COMET study: Safety, immunogenicity, and preliminary efficacy for repeat avalglucosidase alfa dosing in patients with infantile-onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa and demonstrated clinical decline
Publication
, Conference
Kronn, D; Brassier, A; Broomfield, A; Davison, J; Hahn, S; Kishnani, PS; Kumada, S; Labarthe, F; Ohki, H; Pichard, S; Haack, KA; Fleurinck, C ...
Published in: Molecular Genetics and Metabolism
February 2020
Duke Scholars
Published In
Molecular Genetics and Metabolism
DOI
ISSN
1096-7192
Publication Date
February 2020
Volume
129
Issue
2
Start / End Page
S92 / S92
Publisher
Elsevier BV
Related Subject Headings
- Genetics & Heredity
- 3202 Clinical sciences
- 3105 Genetics
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kronn, D., Brassier, A., Broomfield, A., Davison, J., Hahn, S., Kishnani, P. S., … Johnson, J. (2020). Mini-COMET study: Safety, immunogenicity, and preliminary efficacy for repeat avalglucosidase alfa dosing in patients with infantile-onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa and demonstrated clinical decline. In Molecular Genetics and Metabolism (Vol. 129, pp. S92–S92). Elsevier BV. https://doi.org/10.1016/j.ymgme.2019.11.231
Kronn, David, Anaïs Brassier, Alexander Broomfield, James Davison, Sihoun Hahn, Priya S. Kishnani, Satoko Kumada, et al. “Mini-COMET study: Safety, immunogenicity, and preliminary efficacy for repeat avalglucosidase alfa dosing in patients with infantile-onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa and demonstrated clinical decline.” In Molecular Genetics and Metabolism, 129:S92–S92. Elsevier BV, 2020. https://doi.org/10.1016/j.ymgme.2019.11.231.
Kronn D, Brassier A, Broomfield A, Davison J, Hahn S, Kishnani PS, et al. Mini-COMET study: Safety, immunogenicity, and preliminary efficacy for repeat avalglucosidase alfa dosing in patients with infantile-onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa and demonstrated clinical decline. In: Molecular Genetics and Metabolism. Elsevier BV; 2020. p. S92–S92.
Kronn, David, et al. “Mini-COMET study: Safety, immunogenicity, and preliminary efficacy for repeat avalglucosidase alfa dosing in patients with infantile-onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa and demonstrated clinical decline.” Molecular Genetics and Metabolism, vol. 129, no. 2, Elsevier BV, 2020, pp. S92–S92. Crossref, doi:10.1016/j.ymgme.2019.11.231.
Kronn D, Brassier A, Broomfield A, Davison J, Hahn S, Kishnani PS, Kumada S, Labarthe F, Ohki H, Pichard S, Haack KA, Fleurinck C, He S, Johnson J. Mini-COMET study: Safety, immunogenicity, and preliminary efficacy for repeat avalglucosidase alfa dosing in patients with infantile-onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa and demonstrated clinical decline. Molecular Genetics and Metabolism. Elsevier BV; 2020. p. S92–S92.
Published In
Molecular Genetics and Metabolism
DOI
ISSN
1096-7192
Publication Date
February 2020
Volume
129
Issue
2
Start / End Page
S92 / S92
Publisher
Elsevier BV
Related Subject Headings
- Genetics & Heredity
- 3202 Clinical sciences
- 3105 Genetics
- 1103 Clinical Sciences